|
Market Cap (5-Jul) $6,838,995 (1,207th) |
Close (30-Jun) $0.200 |
Volume (30-Jun) 1,808,064 |
Shortsold (12-Jun) 8,499 (0.01%) (521st) |
|
52w High $0.100 |
52w Low $0.059 |
P/E - |
EPS 0 |
IXC released this announcement to the ASX on 8 March 2021, 9:15. The announcement is not marked as price sensitive, and is 3 page(s) in length and 194.29kb in size.
You can view all announcements from IXC and see how they appear on a price chart on the announcements page.
At the date of this announcement, IXC was 0.552% short sold according to ASIC data. It was ranked the 263rd most shorted stock on the ASX. It remains ranked 521st as of the latest reported data (12 June 2025).
| Other Recent Announcements from IXC | |
|---|---|
| Phase III Clinical Trial Update and New IIH Market Analysis | 28 June 2023, 8:40 |
| Invex Granted European Orphan Drug Designation for TBI | 23 June 2023, 8:18 |
| Invex Receives Regulatory Approval for IIH EVOLVE in France | 21 April 2023, 8:17 |
| Postcard to Shareholders | 8 March 2021, 9:15 |
| Notice of General Meeting/Proxy Form | 8 March 2021, 9:12 |
| US Trademark Granted for Presendin | 26 February 2021, 8:50 |
| Initial Director's Interest Notice | 16 February 2021, 13:11 |
You must be logged in to post a reply.
Invex Therapeutics Ltd 